Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors

Zeng,Yi; Ling,Yudong; Chen,Xiaojiang; Ding,Chao; Jin,Yukai; Feng,Shoucheng; Chen,Zhenchong; Guo,Jianrong; Qiu,Haibo

doi:10.3892/ol.2024.14266

Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors

Authors:
- Yi Zeng
- Yudong Ling
- Xiaojiang Chen
- Chao Ding
- Yukai Jin
- Shoucheng Feng
- Zhenchong Chen
- Jianrong Guo
- Haibo Qiu
View Affiliations

Affiliations: Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‑Sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: January 31, 2024 https://doi.org/10.3892/ol.2024.14266
Article Number: 133

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For patients with gastrointestinal stromal tumors (GISTs) and liver metastases, there is still debate about whether radiofrequency ablation (RFA) or hepatectomy is preferable. The present study aimed to compare the clinical outcomes of RFA with hepatectomy in patients with GISTs and liver metastases. The present retrospective study consisted of a cohort of 43 patients who had been diagnosed with liver metastases from GISTs between January 2010 and December 2022. The study included 18 patients who received RFA combined with tyrosine kinase inhibitor (TKI) therapy (RFA group) and 25 patients who underwent hepatectomy combined with TKI therapy (hepatectomy group). For the patients with liver metastases, the progression‑free survival (PFS) rates at 1, 3 and 5 years were 66.5, 38.2 and 33.9%, respectively. Notably, patients in the hepatectomy group exhibited significantly improved PFS times compared with those in the RFA group (median PFS, 42.7 months vs. 14.3 months; P=0.034). Furthermore, the time to imatinib treatment failure (TTF) was notably improved in the hepatectomy group compared with that in the RFA group, and this difference was statistically significant (median TTF, 71.1 vs. 38.0 months; P=0.041). However, the overall survival (OS) times of patients who received RFA and those who had hepatectomy did not differ significantly (median OS, not reached vs. not reached, P=0.120). There was no statistically significant distinction in PFS and TTF between patients who underwent hepatectomy combined with postoperative TKI and those who underwent hepatectomy combined with perioperative TKI (median PFS, 29.5 vs. not reached; P=0.520; median TTF, 66.4 months vs. 71.1 months; P=0.430). The univariate and multivariate analyses consistently identified the sole prognostic factor affecting PFS as hepatectomy combined with TKI therapy (hazard ratio, 0.379; 95% CI, 0.159‑0.899; P=0.028). In conclusion, hepatectomy combined with TKI therapy improved prognosis for patients with liver metastases to a greater extent than RFA combined with TKI therapy. For this type of patient, hepatectomy may be a preferable option.

View Figures

View References

1	Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
2	Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A and Bulusu VR: Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 40:39–46. 2016. View Article : Google Scholar : PubMed/NCBI
3	Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
4	Miettinen M and Lasota J: Gastrointestinal stromal tumors. Gastroenterol Clin North Am. 42:399–415. 2013. View Article : Google Scholar : PubMed/NCBI
5	Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
6	Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol. 17 (Suppl 10):x280–x286. 2006. View Article : Google Scholar : PubMed/NCBI
7	Miettinen M and Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
8	Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
9	Blay JY, Kang YK, Nishida T and von Mehren M: Gastrointestinal stromal tumours. Nat Rev Dis Primers. 7:222021. View Article : Google Scholar : PubMed/NCBI
10	Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 11:4182–4190. 2005. View Article : Google Scholar : PubMed/NCBI
11	Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF and Philip PA: Gastrointestinal stromal tumor: A review of current and emerging therapies. Cancer Metastasis Rev. 40:625–641. 2021. View Article : Google Scholar : PubMed/NCBI
12	Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T and Doi T: Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): A randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 33:959–967. 2022. View Article : Google Scholar : PubMed/NCBI
13	Chen Q, Li C, Yang H, Zhao H, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, Zhou J and Cai J: Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China. Clin Res Hepatol Gastroenterol. 43:317–323. 2019. View Article : Google Scholar : PubMed/NCBI
14	Yoon IS, Shin JH, Han K, Kim PN, Kim KH, Kang YK and Ko HK: Ultrasound-guided intraoperative radiofrequency ablation and surgical resection for liver metastasis from malignant gastrointestinal stromal tumors. Korean J Radiol. 19:542018. View Article : Google Scholar : PubMed/NCBI
15	Xue A, Gao X, He Y, Shu P, Huang X, Sun J, Lu J, Hou Y, Fang Y and Shen K: Role of surgery in the management of liver metastases from gastrointestinal stromal tumors. Front Oncol. 12:9034872022. View Article : Google Scholar : PubMed/NCBI
16	Yamanaka T, Takaki H, Nakatsuka A, Uraki J, Fujimori M, Hasegawa T, Sakuma H and Yamakado K: Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol. 24:341–346. 2013. View Article : Google Scholar : PubMed/NCBI
17	DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM and Brennan MF: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg. 231:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
18	Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G and Vincenzi B: New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 11:17588359198419462019. View Article : Google Scholar : PubMed/NCBI
19	Jung JH, Won HJ, Shin YM and Kim PN: Safety and efficacy of radiofrequency ablation for hepatic metastases from gastrointestinal stromal tumor. J Vasc Interv Radiol. 26:1797–1802. 2015. View Article : Google Scholar : PubMed/NCBI
20	Jones RL, McCall J, Adam A, O'Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C and Judson IR: Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol. 36:477–482. 2010. View Article : Google Scholar : PubMed/NCBI
21	Keung EZ, Raut CP and Rutkowski P: The landmark series: Systemic therapy for resectable gastrointestinal stromal tumors. Ann Surg Oncol. 27:3659–3671. 2020. View Article : Google Scholar : PubMed/NCBI
22	DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH and Brennan MF: Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 234:540–548. 2001. View Article : Google Scholar : PubMed/NCBI
23	Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, Tsung A, Pawlik TM and Clary BM: Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 118:3571–3578. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen Q, Li C, Yang H, Zhao H, Wu J, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, et al: Resection combined with TKI therapy for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China. J Gastrointest Surg. 24:1330–1341. 2020. View Article : Google Scholar : PubMed/NCBI
25	Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C and de Wilt JH; Dutch Liver Surgery Working Group, : Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol. 42:1407–1413. 2016. View Article : Google Scholar : PubMed/NCBI
26	DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF and Antonescu CR: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 245:347–352. 2007. View Article : Google Scholar : PubMed/NCBI
27	Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J and Füzesi L: Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 14:526–532. 2007. View Article : Google Scholar : PubMed/NCBI
28	Vassos N, Agaimy A, Hohenberger W and Croner RS: Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol. 14:531–539. 2015. View Article : Google Scholar : PubMed/NCBI